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Early identification of children with high risk of asthma is often based on atopic characteristics, especially aeroallergen sensitization, which however is rarely detectable from early infancy. Human rhinovirus (HRV)‐associated wheeze has been suggested as a new, significant and early risk factor for recurrent wheezing and later asthma [1](#pai12046-bib-0001){ref-type="ref"}, [2](#pai12046-bib-0002){ref-type="ref"}, [3](#pai12046-bib-0003){ref-type="ref"}. Of the long‐term follow‐up studies on HRV‐wheeze, only one study has focused on the first episode of lower airways infection [3](#pai12046-bib-0003){ref-type="ref"}, but it showed a positive link between HRV aetiology and recurrent wheezing in a 12‐month follow‐up. Moreover, susceptibility to more severe HRV infections has been linked to atopic characteristics and low interferon levels *in vivo* [4](#pai12046-bib-0004){ref-type="ref"}, [5](#pai12046-bib-0005){ref-type="ref"}, [6](#pai12046-bib-0006){ref-type="ref"}, [7](#pai12046-bib-0007){ref-type="ref"}, [8](#pai12046-bib-0008){ref-type="ref"}, [9](#pai12046-bib-0009){ref-type="ref"} and epithelial damage *in vitro* [10](#pai12046-bib-0010){ref-type="ref"}.

The main treatment strategies of recurrent wheezing and exacerbations of asthma rely on inhaled and systemic corticosteroids, but these drugs have not been effective in early wheezing in most studies [11](#pai12046-bib-0011){ref-type="ref"}, [12](#pai12046-bib-0012){ref-type="ref"}. One problem has been the identification of high asthma risk children early. We have shown in a *post‐hoc* analysis of a controlled trial that oral prednisolone treatment of the first wheezing episode reduced recurrent wheezing in children with HRV aetiology and/or eczema in a 1‐yr follow‐up [13](#pai12046-bib-0013){ref-type="ref"}. Other efficacy studies have not investigated HRV aetiology. We have now completed a 7‐yr follow‐up of the same first‐time wheezing cohort. We aimed to evaluate the risk factors for recurrent wheezing and to assess the effect of prednisolone treatment on the development of recurrent wheezing overall and in pre‐specified subgroups according to viral aetiology and eczema status.

Methods {#pai12046-sec-0006}
=======

Study subjects {#pai12046-sec-0007}
--------------

The Vinku study (vinku means wheeze in Finnish) was carried out in the Department of Paediatrics, Turku University Hospital (Turku, Finland) from September, 2000 to May, 2002 as previously described [13](#pai12046-bib-0013){ref-type="ref"}. Only those experiencing their first episode of wheezing and being aged \<3 yr were included in the long‐term follow‐up (Fig. [1](#pai12046-fig-0001){ref-type="fig"}) [13](#pai12046-bib-0013){ref-type="ref"}. The study was approved by the Ethics Committee of the Turku University Hospital and was commenced only after obtaining written informed consent from the guardian.

![Study flow chart.](PAI-24-237-g001){#pai12046-fig-0001}

Study design {#pai12046-sec-0008}
------------

Originally, the Vinku study was a randomized double‐blind placebo‐controlled paralleled trial investigating the efficacy of oral prednisolone in wheezing children overall and seeking patient characteristics which could explain a beneficial response to the drug [13](#pai12046-bib-0013){ref-type="ref"}. Viral aetiology was our special interest [14](#pai12046-bib-0014){ref-type="ref"}, [15](#pai12046-bib-0015){ref-type="ref"}. Study physicians interviewed their parents before inclusion in the study. The first wheezing episode ever was determined based on parental interview and revision of medical records. On the ward nasopharyngeal aspirate sample was taken, blood sample was drawn, and then all children were randomized to receive either oral prednisolone (first dose 2 mg/kg, then 2 mg/kg/day in three divided doses for 3 days, maximum dose 60 mg/day, Prednisolon^®^ 5 mg tablets, Leiras, Helsinki, Finland) or a placebo. No stratified randomization was carried out for eligible participants because the long‐term follow‐up protocol was implemented during the efficacy trial.

Long‐term follow‐up visit was arranged at 12 months [13](#pai12046-bib-0013){ref-type="ref"} (Fig. [1](#pai12046-fig-0001){ref-type="fig"}) and thereafter the hospital records of the 111 study children were reviewed for wheezing episodes and medications for 7 yr.

Outcome {#pai12046-sec-0009}
-------

The primary outcome was time to recurrent wheezing ever. It was defined as the earliest date during the 7‐yr follow‐up period when a child fulfilled one or more of the following criteria: three physician‐confirmed episodes of wheezing within the past 12 months; continuous lower respiratory symptoms (cough, wheezing) lasting \>4 wk and relieved by recurrent use of bronchodilators; or moderate‐to‐severe wheezing episodes necessitating systemic corticosteroid use within 6 months [16](#pai12046-bib-0016){ref-type="ref"}.

Definitions {#pai12046-sec-0010}
-----------

Wheezing was defined as high‐pitched whistling sound in expiratory breathing [16](#pai12046-bib-0016){ref-type="ref"}. The children were divided to three virus groups. The HRV group included 34 children (30%) \[monoinfection (n = 16) or virus co‐infection (n = 18 where six cases with respiratory syncytial virus (RSV) co‐infection)\], the RSV group 44 children (40%) \[monoinfection (n = 27) or co‐infection excluding HRV (n = 17)\] and the HRV‐/RSV‐negative group 33 children (30%) \[no virus (n = 6), monoinfection (n = 21) or co‐infection (n = 6)\]. The same grouping was used in our previous report [13](#pai12046-bib-0013){ref-type="ref"} and based on the earlier hypothesis that HRV is more significant risk factor for recurrent wheezing than RSV [1](#pai12046-bib-0001){ref-type="ref"}, [2](#pai12046-bib-0002){ref-type="ref"}.

Allergic sensitization was defined as positive immunoglobulin (Ig) E antibodies to any of common allergen as previously described (cut‐off level 0.35 kU/l, fluoro‐enzyme immunoassay, CAP FEIA, Phadiatop Combi^®^, Phadia, Uppsala, Sweden) [6](#pai12046-bib-0006){ref-type="ref"}, [13](#pai12046-bib-0013){ref-type="ref"}. A cut‐off value for increased eosinophil count was ≥0.40 × 10^9^/l.

Eczema was a physician‐made diagnosis according to typical symptoms that included pruritus, typical morphology and chronicity of disease. Eczema was defined as atopic eczema if a child was sensitized to any allergen.

Virus and questionnaire data {#pai12046-sec-0011}
----------------------------

The nasopharyngeal aspirates were analysed for 18 viruses: adenovirus, coronaviruses (229E, OC43, NL63 and HKU1), enteroviruses, human bocavirus (HBoV), human metapneumovirus (hMPV), HRV, influenza A and B, parainfluenza virus (PIV) types 1--4, polyomaviruses WU and KI, and RSV using PCR or conventional methods for all viruses when applicable [14](#pai12046-bib-0014){ref-type="ref"}, [15](#pai12046-bib-0015){ref-type="ref"}. Blood eosinophil counts and allergen‐specific IgE antibodies were measured by the routine diagnostics of the Central Laboratory of Turku University Hospital [6](#pai12046-bib-0006){ref-type="ref"}. A standardized questionnaire on host and environment‐related risk factors for recurrent wheezing was used in parental interview (Data S1).

Statistical analysis {#pai12046-sec-0012}
--------------------

Host and environment‐related risk factors were analysed with Kruskal--Wallis [anova]{.smallcaps}, Mann--Whitney U test, or χ^2^ test when appropriate. Univariable Cox proportional‐hazards regression was used to analyse risk factors for recurrent wheezing, that is, parental asthma, any sensitization, eczema, day care, parental smoking, age at study entry, sex and viral aetiology. The analysis was repeated using multivariable backward stepwise model (exclusion criteria p \> 0.10) including the same factors. Only the significant risk factors (p \< 0.05) were included as covariates in the final model. Cox hazard ratio (HR) indicated the risk of recurrent wheezing. Interactions between treatment grouping (prednisolone vs. placebo) and pre‐specified risk factors (eczema status and HRV, RSV or HRV‐/RSV‐negative aetiology) were studied with Cox regression [13](#pai12046-bib-0013){ref-type="ref"}. Multivariable model was repeated with significant interactions [13](#pai12046-bib-0013){ref-type="ref"}. Each study subject was censored from the analysis after the initiation of the daily controller therapy with inhaled corticosteroid treatment. Analyses were made using [pasw]{.smallcaps} 18.0 software (SPSS Inc, Chicago, Ill, USA).

Results {#pai12046-sec-0013}
=======

Study population {#pai12046-sec-0014}
----------------

The long‐term follow‐up criteria were fulfilled by 131 children (Fig. [1](#pai12046-fig-0001){ref-type="fig"}). Of these, nine children were lost to follow‐up, and 11 children were excluded from the analysis because inhaled corticosteroid was used for prolonged cough. Finally, 111 (85%) children were included. The prednisolone (n = 55) and placebo (n = 56) recipients were equally distributed overall and according to the risk factor characteristics (Fig. [1](#pai12046-fig-0001){ref-type="fig"} and Table [1](#pai12046-tbl-0001){ref-type="table"}).

###### 

Distribution of risk factors at the study entry

                                                         7‐yr follow‐up                                                          
  ------------------------------------------------------ ---------------- ---------- ---------- ---------- ---------- ---------- ----------
                                                         111              51 (46%)   24 (47%)   27 (53%)   60 (54%)   31 (52%)   29 (48%)
  Age                                                                                                                            
  3--11 months                                           51 (46%)         27 (53%)   12 (44%)   15 (56%)   24 (47%)   13 (54%)   11 (46%)
  12--35 months                                          60 (54%)         24 (40%)   12 (50%)   12 (50%)   36 (60%)   18 (50%)   18 (50%)
  Sex                                                                                                                            
  Male                                                   75 (68%)         37 (49%)   18 (49%)   19 (51%)   38 (51%)   16 (42%)   22 (58%)
  Female                                                 36 (32%)         14 (39%)   6 (43%)    8 (57%)    22 (61%)   15 (68%)   7 (32%)
  Eczema                                                                                                                         
  Yes                                                    36 (32%)         20 (56%)   7 (35%)    13 (65%)   16 (44%)   8 (50%)    8 (50%)
  No                                                     75 (68%)         31 (41%)   17 (55%)   14 (45%)   44 (59%)   23 (52%)   21 (48%)
  Sensitization[a](#pai12046-note-0002){ref-type="fn"}                                                                           
  Any allergen                                           16 (14%)         11 (69%)   6 (55%)    5 (45%)    5 (31%)    2 (40%)    3 (60%)
  None                                                   95 (86%)         40 (42%)   18 (45%)   22 (55%)   55 (58%)   29 (53%)   26 (47%)
  Food allergens                                         16 (14%)         11 (69%)   7 (64%)    4 (36%)    5 (31%)    2 (40%)    3 (60%)
  Aeroallergens                                          3 (3%)           3 (100%)   1 (33%)    2 (67%)    0 (0%)     0 (0%)     0 (0%)
  Seasonal allergens                                     3 (3%)           3 (100%)   1 (33%)    2 (67%)    0 (0%)     0 (0%)     0 (0%)
  Perennial allergens                                    2 (2%)           2 (100%)   1 (50%)    1 (50%)    0 (0%)     0 (0%)     0 (0%)
  Blood eosinophil count                                                                                                         
  \<0.4 × 10^9^/l                                        81 (73%)         39 (48%)   19 (49%)   20 (51%)   42 (52%)   23 (55%)   19 (45%)
  ≥0.4 × 10^9^/l                                         30 (27%)         12 (40%)   5 (42%)    7 (58%)    18 (60%)   8 (44%)    10 (56%)
  Parental asthma                                        18 (16%)         8 (44%)    5 (63%)    3 (37%)    10 (56%)   5 (50%)    5 (50%)
  Parental smoking                                       48 (43%)         23 (48%)   10 (43%)   13 (57%)   25 (52%)   11 (44%)   14 (56%)
  Day care                                                                                                                       
  Home                                                   78 (70%)         35 (45%)   16 (46%)   19 (54%)   43 (55%)   25 (58%)   18 (42%)
  Family day care                                        17 (15%)         6 (35%)    4 (67%)    2 (33%)    11 (65%)   4 (36%)    7 (64%)
  Group nursery                                          16 (14%)         10 (63%)   4 (40%)    6 (60%)    6 (37%)    2 (33%)    4 (67%)
  Viral aetiology                                                                                                                
  RSV                                                    44 (40%)         12 (27%)   7 (58%)    5 (42%)    32 (73%)   18 (56%)   14 (44%)
  HRV                                                    34 (30%)         19 (56%)   7 (37%)    12 (63%)   15 (44%)   10 (67%)   5 (33%)
  HRV‐/RSV‐negative                                      33 (30%)         20 (61%)   10 (50%)   10 (50%)   13 (39%)   3 (23%)    10 (77%)

Data presented as n (%). RSV, respiratory syncytial virus; HRV, human rhinovirus.

Sensitization was defined as positive immunoglobulin (Ig) E antibodies to any of the common allergens (cut‐off level 0.35 kU/l for codfish, cow\'s milk, egg, peanut, soybean, wheat, cat, dog, horse, birch, mugwort, timothy, *Cladosporium herbarum* and *Dermatophagoides pteronyssinus*; fluoro‐enzyme immunoassay, CAP FEIA, Phadiatop Combi^®^, Phadia, Uppsala, Sweden). Aeroallergen sensitization was defined as IgE antibodies to any of the latter eight allergens, which were divided into perennial (dog, cat or *D. pteronyssinus*) and seasonal (birch, mugwort, timothy and *C. herbarum)*.
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Patient characteristics {#pai12046-sec-0015}
-----------------------

Median age of the study children was 12 months (interquartile range 7, 18 months) at study entry and at the end of follow‐up 8.0 yr (7.3, 8.7 yr, respectively). At study entry, 75 of 111 (68%) children were boys, 36 of 111 (32%) had eczema, 16 of 109 (14%) were sensitized and 106 of 111 (95%) children were virus‐positive. The HRV group had a higher prevalence of allergic sensitization (29%) than the other groups (RSV 7%; HRV‐/RSV‐negative 9%, p = 0.010). The RSV group had a lower prevalence of blood eosinophil count ≥0.4 × 10^9^/l (7%) than the other groups (HRV 44%; HRV‐/RSV‐negative 36%, p = 0.001). Sensitized children were older than non‐sensitized (medians 16 vs. 11 months, p = 0.003). Otherwise, no differences were found in descriptive statistics between risk factor groups stated in Table [1](#pai12046-tbl-0001){ref-type="table"} or between prednisolone and placebo groups.

Risk factors for recurrent wheezing {#pai12046-sec-0016}
-----------------------------------

During the 7‐yr follow‐up, 51 (46%) of the 111 study children suffered from recurrent wheezing: 90% (46/51) of children fulfilled the criterion of three physician‐confirmed wheezing episodes within the past 12 months; 12% (6/51) the criterion of continuous lower respiratory symptoms lasting \>4 wk; and 2% (1/51) the criterion of ≥2 wheezing episodes necessitating systemic corticosteroid within 6 months. Two children had two positive criteria; either continuous symptoms or systemic corticosteroid use with concomitant recurrent wheezing.

The univariable analysis showed that sensitization at study entry was a risk factor for recurrent wheezing (HR 2.25, 95% CI 1.15--4.41). Sensitization was divided into aeroallergen (4.40, 1.35--14.3, respectively, n = 3) and to food‐allergen sensitizations (2.28, 1.17--4.46, respectively, n = 16). All three children with aeroallergen sensitization had recurrent wheezing. Otherwise, no significant risk factors were found in univariable model.

In the final model of backward stepwise multivariable analysis, the risk factors for recurrent wheezing were HRV (HR 3.54, 95% CI 1.51--8.30), sensitization (3.47, 1.55--8.30, respectively), age \<1 yr (2.45, 1.29--4.65) and eczema at study entry (2.33, 1.11--4.90). The incidence of recurrent wheezing was 56% (19/34) in children with HRV wheezing, 69% (11/16) in children with sensitization, 53% (27/51) in children aged \<1 yr and 56% (20/36) in children with eczema (Table [1](#pai12046-tbl-0001){ref-type="table"}).

Efficacy of prednisolone {#pai12046-sec-0017}
------------------------

Prednisolone showed no overall efficacy in reducing recurrent wheezing (Fig. [2](#pai12046-fig-0002){ref-type="fig"}, Table [1](#pai12046-tbl-0001){ref-type="table"}). Then the Cox regression analysis was performed in pre‐specified subgroups demonstrating an interaction between treatment grouping and viral aetiology (p = 0.029) or eczema (p = 0.033). Prednisolone treatment was associated with less recurrent wheezing in HRV‐affected children (non‐adjusted HR 0.37, 95% CI 0.15--0.95; HR adjusted for young age, sensitization, eczema and parental asthma 0.32, 95% CI 0.12--0.90), but not in RSV‐affected (0.74, 0.27--2.03; 0.73, 0.25--2.10, respectively), nor in the HRV‐/RSV‐negative group (1.73, 0.72--4.19; 1.74, 0.68--4.45; Fig. [2](#pai12046-fig-0002){ref-type="fig"} and Table [1](#pai12046-tbl-0001){ref-type="table"}). Prednisolone treatment was associated with less recurrent wheezing in children with eczema (non‐adjusted HR 0.53, 95% CI 0.21--1.33; HR adjusted for sensitization, young age, viral aetiology and parental asthma 0.27, 95% CI 0.08--0.87), but not in those without eczema (1.12, 0.55--2.28; 1.45, 0.69--3.04, respectively) (Fig. [2](#pai12046-fig-0002){ref-type="fig"}). The incidence of recurrent wheezing in the prednisolone vs. placebo groups was 41% (7/17) vs. 71% (12/17) in children with HRV and 47% (7/15) vs. 62% (13/21) in children with eczema.

![Risk of recurrent wheezing in prednisolone (bold line) and placebo recipients during a 7‐yr follow‐up. Prednisolone treatment was not associated with overall efficacy in preventing recurrent wheezing, but the treatment was associated with less recurrent wheezing in HRV and/or eczema group. In the HRV‐/RSV‐negative group, there were too few cases in prednisolone recipients with recurrent wheezing (n = 3) for statistical analysis. RSV, respiratory syncytial virus; HRV, human rhinovirus.](PAI-24-237-g002){#pai12046-fig-0002}

Discussion {#pai12046-sec-0018}
==========

This is the first study to investigate the long‐term (up to school age) prognosis of the first wheezing episode with the inclusion of full virology and atopic characteristics. Moreover, because the cohort was primarily randomized to receive prednisolone or placebo, we were able to assess the long‐term efficacy of oral prednisolone in this unique setting *post‐hoc*. We show that especially aeroallergen sensitization (HR4.4) and HRV aetiology (HR 3.5) are important predictive factors for recurrent wheezing already at the time of the first wheezing episode [2](#pai12046-bib-0002){ref-type="ref"}, [3](#pai12046-bib-0003){ref-type="ref"}, [6](#pai12046-bib-0006){ref-type="ref"}, [8](#pai12046-bib-0008){ref-type="ref"}, [9](#pai12046-bib-0009){ref-type="ref"}, [17](#pai12046-bib-0017){ref-type="ref"}. As a new and provocative finding, we found that oral prednisolone treatment decreased the risk of recurrent wheezing in children with HRV aetiology and/or eczema, and that the effect persisted the full 7 yr follow‐up period.

Our finding on HRV‐associated risk of recurrent wheezing agrees with the Italian cohort that also focused on the first episode of lower airways infection [3](#pai12046-bib-0003){ref-type="ref"} and other early wheezing cohorts [1](#pai12046-bib-0001){ref-type="ref"}, [2](#pai12046-bib-0002){ref-type="ref"}, [9](#pai12046-bib-0009){ref-type="ref"}. The HRV‐associated risk has been explained by the increased susceptibility to lower airway HRV infections in individuals with pronounced atopic characteristics (allergen‐specific IgE sensitization, increased exhaled nitric oxide levels, increased blood eosinophil counts, atopic eczema, maternal atopic eczema and/or increased IL‐4, IL‐5, and IL‐13 responses in airway secretions), damaged airway epithelium, as well as decreased interferon α/β/γ/λ and IL‐10 responses in airway secretions or cells [1](#pai12046-bib-0001){ref-type="ref"}, [4](#pai12046-bib-0004){ref-type="ref"}, [5](#pai12046-bib-0005){ref-type="ref"}, [6](#pai12046-bib-0006){ref-type="ref"}, [7](#pai12046-bib-0007){ref-type="ref"}, [8](#pai12046-bib-0008){ref-type="ref"}, [9](#pai12046-bib-0009){ref-type="ref"}, [10](#pai12046-bib-0010){ref-type="ref"}, [18](#pai12046-bib-0018){ref-type="ref"}, [19](#pai12046-bib-0019){ref-type="ref"}. In line with these findings, our first‐time wheezing HRV‐affected children were more sensitized at study entry compared with other virus groups (29% vs. 7--9%). Moreover, compared with RSV, HRV‐induced wheezing has been connected to early decreased lung function, more severe illness and in high‐risk cohorts to earlier wheezing illness [20](#pai12046-bib-0020){ref-type="ref"}.

Eczema is classically the earliest manifestation of atopic march followed by food allergy, wheezing/asthma and allergic rhinitis. A recent meta‐analysis of 13 prospective cohort studies (four birth cohorts and nine eczema cohorts) studies showed OR 2.1 for the risk of asthma after eczema [21](#pai12046-bib-0021){ref-type="ref"}. Our finding on eczema‐associated risk of recurrent wheezing (HR 2.3) is in line with these earlier data. Eczema and asthma may involve mutual genetic mechanisms [22](#pai12046-bib-0022){ref-type="ref"}, but these were not investigated here.

Sensitization, especially to aeroallergens, is an important predictive factor for recurrent wheezing found by us and others (OR 3--16) [2](#pai12046-bib-0002){ref-type="ref"}, [6](#pai12046-bib-0006){ref-type="ref"}, [9](#pai12046-bib-0009){ref-type="ref"}, [17](#pai12046-bib-0017){ref-type="ref"}, [23](#pai12046-bib-0023){ref-type="ref"} and showed stronger predictive value than HRV. Sensitization may be a predisposing factor for HRV illnesses in later life, possibly by suppressing antiviral responses [8](#pai12046-bib-0008){ref-type="ref"}, [19](#pai12046-bib-0019){ref-type="ref"}. In our study, however, there were only three aeroallergen‐sensitized children, but they all developed recurrent wheezing. Aeroallergen sensitization is highly specific, but not sensitive early risk marker for asthma [17](#pai12046-bib-0017){ref-type="ref"}, [23](#pai12046-bib-0023){ref-type="ref"}. The slow development of aeroallergen sensitization in general population (rarely before age 1 yr) [5](#pai12046-bib-0005){ref-type="ref"}, [23](#pai12046-bib-0023){ref-type="ref"} decreases its value in asthma risk indices at early life and calls for better early risk factors such as HRV. Thus, our data suggest that early asthma risk indices could be improved if the HRV aetiology was included [24](#pai12046-bib-0024){ref-type="ref"}.

Our findings on the efficacy of prednisolone in HRV and/or eczema affected children are supported by others [1](#pai12046-bib-0001){ref-type="ref"}, [5](#pai12046-bib-0005){ref-type="ref"}, [6](#pai12046-bib-0006){ref-type="ref"}, [8](#pai12046-bib-0008){ref-type="ref"}, [9](#pai12046-bib-0009){ref-type="ref"}, suggesting that HRV‐wheeze and eczema are most likely linked to a pre‐existing, partly atopy‐related, inflammation in the airways [25](#pai12046-bib-0025){ref-type="ref"} and that prednisolone may effectively down‐regulate this inflammation [26](#pai12046-bib-0026){ref-type="ref"}, [27](#pai12046-bib-0027){ref-type="ref"} when administered early. Systemic dosing may particulary be important because it has recently been suggested that a local inflammation triggers a linkage to bone marrow from where cells potentially migrate to their different peripheral targets, for example lungs or skin [25](#pai12046-bib-0025){ref-type="ref"}. Although glucocorticoids preserve epithelial barrier and thereby could protect against respiratory viral infections [28](#pai12046-bib-0028){ref-type="ref"}, a more important mechanism may be their ability to repress the transcription of many inflammatory genes and/or their transcription factors and induce the expression of a number of anti‐inflammatory genes [26](#pai12046-bib-0026){ref-type="ref"}, [27](#pai12046-bib-0027){ref-type="ref"}. Moreover, glucocorticoids inhibit the HRV‐induced up‐regulation of its own receptor ICAM‐1 (intercellular adhesion molecule‐1, major HRV‐receptor) in pulmonary mucosa [29](#pai12046-bib-0029){ref-type="ref"}. Early administration, that is, for the first wheeze and early course of the acute illness may be a relevant factor for the long‐term clinical efficacy. The outcome of recurrent wheezing was almost completely fulfilled within the first 2 yr of follow‐up in our study.

Although the age range was rather broad (3--35 months, median 12 months), 86% were aged \<2 yr which makes our study cohort and results overall very similar to another hospitalized population‐based study, Kuopio bronchiolitis study [1](#pai12046-bib-0001){ref-type="ref"}. However, the risk of recurrent wheeze in our study was inversely dependent on age, whereas other separate cohort studies on hospitalized children with lower respiratory symptoms have suggested that the risk increases by age: the OR was 3.3 for recurrent wheeze in children with bronchiolitis aged less \<12 months (median age 2 months) [3](#pai12046-bib-0003){ref-type="ref"}, and OR was 4.1 for asthma in school age in wheezing children aged \<2 yr [1](#pai12046-bib-0001){ref-type="ref"}. A potential explanation for the discrepancy could be that we studied infants with wheezing only (vs. bronchiolitis with or without wheezing in other studies). Infant wheezing may truly be an important risk factor for asthma, and studies on bronchiolitis should clearly define wheezing status of the subjects. In a high‐risk cohort, the risk of recurrent wheezing has been markedly higher in rhinovirus‐affected wheezing children than in other children and increased by age from the wheezing at first year of life (OR 10) to third year of life (OR 26) [2](#pai12046-bib-0002){ref-type="ref"}.

The strengths of our study are comprehensive assessments of virus aetiology and atopic characteristics, no delay in study drug initiation, long‐term follow‐up, verification of wheezing episodes from hospital/health care records and the use of the non‐selected population. The verification of wheeze was important because the highest odds ratios for recurrent wheeze have been reported in wheezing children [1](#pai12046-bib-0001){ref-type="ref"}, [2](#pai12046-bib-0002){ref-type="ref"}, [9](#pai12046-bib-0009){ref-type="ref"}, [17](#pai12046-bib-0017){ref-type="ref"}. Ninety per cent of the primary outcomes were fulfilled by the definition of episodic wheeze which was defined slightly different from National Asthma Education and Prevention Program (NAEPP) [16](#pai12046-bib-0016){ref-type="ref"}. Here and in our previous report, we used three physician‐confirmed wheezing episodes within a past year according to the Finnish practice [13](#pai12046-bib-0013){ref-type="ref"}. Of other limitations, the study population was rather small, and we focused only on new diagnoses during the follow‐up according to our previous report instead of current asthma [13](#pai12046-bib-0013){ref-type="ref"}. Although the study design was randomized and controlled, the subgroup analyses were carried out *post‐hoc*. The risk of bias of multiple comparisons was avoided by using pre‐specified subgroups. Prospective intervention studies on HRV‐induced wheezing are challenging because virus PCR detection usually is an over‐night diagnosis. Upper airway samples for virus PCR analysis are considered to adequately reflect the infection status in the lower airways [30](#pai12046-bib-0030){ref-type="ref"}.

In conclusion, our data from first‐time wheezing children support the link between atopic characteristics and HRV aetiology. It also strengthens the role of HRV aetiology as an early risk marker for recurrent wheezing [3](#pai12046-bib-0003){ref-type="ref"}, [13](#pai12046-bib-0013){ref-type="ref"}. The reduction in recurrent wheezing by prednisolone in children with HRV and/or eczema suggests that pre‐existing, atopy‐related, inflammation in the airways increases susceptibility to HRV‐wheeze. Prospective randomized trials are warranted to test the hypothesis that early anti‐inflammatory treatment reduces recurrent wheezing in high asthma risk children.
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